FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3010679400> ?p ?o ?g. }

• W3010679400 endingPage "2044" @default.
• W3010679400 startingPage "2031" @default.
• W3010679400 abstract "Abstract Multiple myeloma is an incurable refractory hematologic malignancy arising from plasma cells in the bone marrow. Here we investigated miR-26a function in multiple myeloma and tested single-wall carbon nanotube delivery of miR-26a in vitro and in vivo. miR-26a was downregulated in patients with multiple myeloma cells compared with plasma cells from healthy donors. miR-26a overexpression inhibited proliferation and migration and induced apoptosis in multiple myeloma cell lines. To identify the targets of miR-26a, RPMI8226-V-miR-26-GFP and RPMI8226-V-GFP cells were cultured using stable isotope labeling by amino acids in cell culture (SILAC) medium, followed by mass spectrometry analysis. In multiple myeloma cells overexpressing miR-26a, CD38 protein was downregulated and subsequently confirmed to be a direct target of miR-26a. Depletion of CD38 in multiple myeloma cells duplicated the multiple myeloma inhibition observed with exogenous expression of miR-26a, whereas restoration of CD38 overcame the inhibition of miR-26a in multiple myeloma cells. In a human multiple myeloma xenograft mouse model, overexpression of miR-26a inhibited CD38 expression, provoked cell apoptosis, and inhibited cell proliferation. Daratumumab is the first CD38 antibody drug for monotherapy and combination therapy for patients with multiple myeloma, but eventually resistance develops. In multiple myeloma cells, CD38 remained at low level during daratumumab treatment, but a high-quality response is sustained. In daratumumab-resistant multiple myeloma cells, CD38 expression was completely restored but failed to correlate with daratumumab-induced cell death. Therefore, a therapeutic strategy to confer selection pressure to maintain low CD38 expression in multiple myeloma cells may have clinical benefit. Significance: These results highlight the tumor suppressor function of miR-26a via its targeting of CD38 and suggest the therapeutic potential of miR-26a in patients with multiple myeloma." @default.
• W3010679400 created "2020-03-23" @default.
• W3010679400 creator A5007911294 @default.
• W3010679400 creator A5007951489 @default.
• W3010679400 creator A5010773428 @default.
• W3010679400 creator A5013500379 @default.
• W3010679400 creator A5027080346 @default.
• W3010679400 creator A5029581804 @default.
• W3010679400 creator A5032447166 @default.
• W3010679400 creator A5032464400 @default.
• W3010679400 creator A5034236333 @default.
• W3010679400 creator A5038047695 @default.
• W3010679400 creator A5041718435 @default.
• W3010679400 creator A5045740077 @default.
• W3010679400 creator A5047318164 @default.
• W3010679400 creator A5049282854 @default.
• W3010679400 creator A5059835555 @default.
• W3010679400 creator A5060214040 @default.
• W3010679400 creator A5066709583 @default.
• W3010679400 creator A5072484302 @default.
• W3010679400 creator A5080121245 @default.
• W3010679400 creator A5084566787 @default.
• W3010679400 creator A5085409966 @default.
• W3010679400 creator A5085974329 @default.
• W3010679400 date "2020-05-15" @default.
• W3010679400 modified "2023-10-16" @default.
• W3010679400 title "Targeting of CD38 by the Tumor Suppressor miR-26a Serves as a Novel Potential Therapeutic Agent in Multiple Myeloma" @default.
• W3010679400 cites W145754928 @default.
• W3010679400 cites W1600286956 @default.
• W3010679400 cites W1916436059 @default.
• W3010679400 cites W1967812459 @default.
• W3010679400 cites W1970854602 @default.
• W3010679400 cites W1975437957 @default.
• W3010679400 cites W1977179502 @default.
• W3010679400 cites W1989069691 @default.
• W3010679400 cites W1993469143 @default.
• W3010679400 cites W1994079577 @default.
• W3010679400 cites W2000130439 @default.
• W3010679400 cites W2000903359 @default.
• W3010679400 cites W2002917664 @default.
• W3010679400 cites W2049702532 @default.
• W3010679400 cites W2053937978 @default.
• W3010679400 cites W2060520161 @default.
• W3010679400 cites W2093175031 @default.
• W3010679400 cites W2096207943 @default.
• W3010679400 cites W2096439168 @default.
• W3010679400 cites W2103562758 @default.
• W3010679400 cites W2107277218 @default.
• W3010679400 cites W2111480476 @default.
• W3010679400 cites W2113261463 @default.
• W3010679400 cites W2115397405 @default.
• W3010679400 cites W2119389886 @default.
• W3010679400 cites W2123894642 @default.
• W3010679400 cites W2141105112 @default.
• W3010679400 cites W2146483998 @default.
• W3010679400 cites W2147997023 @default.
• W3010679400 cites W2148276874 @default.
• W3010679400 cites W2149385948 @default.
• W3010679400 cites W2150696691 @default.
• W3010679400 cites W2151371056 @default.
• W3010679400 cites W2154811915 @default.
• W3010679400 cites W2158214783 @default.
• W3010679400 cites W2159807040 @default.
• W3010679400 cites W2192080449 @default.
• W3010679400 cites W2402981337 @default.
• W3010679400 cites W2472135629 @default.
• W3010679400 cites W2493766266 @default.
• W3010679400 cites W2549396793 @default.
• W3010679400 cites W2566975644 @default.
• W3010679400 cites W2592248309 @default.
• W3010679400 cites W2595650684 @default.
• W3010679400 cites W2605597231 @default.
• W3010679400 cites W2608087858 @default.
• W3010679400 cites W2611004920 @default.
• W3010679400 cites W2744185357 @default.
• W3010679400 cites W2756422634 @default.
• W3010679400 cites W2767256995 @default.
• W3010679400 cites W2769576511 @default.
• W3010679400 cites W2772566228 @default.
• W3010679400 cites W2772713217 @default.
• W3010679400 cites W2776818949 @default.
• W3010679400 cites W2789891087 @default.
• W3010679400 cites W2891882983 @default.
• W3010679400 cites W2893245372 @default.
• W3010679400 cites W2900177908 @default.
• W3010679400 cites W2909546334 @default.
• W3010679400 cites W2979605740 @default.
• W3010679400 doi "https://doi.org/10.1158/0008-5472.can-19-1077" @default.
• W3010679400 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7231653" @default.
• W3010679400 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32193289" @default.
• W3010679400 hasPublicationYear "2020" @default.
• W3010679400 type Work @default.
• W3010679400 sameAs 3010679400 @default.
• W3010679400 citedByCount "29" @default.
• W3010679400 countsByYear W30106794002020 @default.
• W3010679400 countsByYear W30106794002021 @default.
• W3010679400 countsByYear W30106794002022 @default.
• W3010679400 countsByYear W30106794002023 @default.

• next